PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Two year result of intravitreal bevacizumab for diabetic macular edema using treat and extend protocol.

Abstract To determine the efficacy of the treat and extend (TAE) protocol with intravitreal bevacizumab (IVB) for managing diabetic macular edema (DME).Retrospective, single-center study.For this retrospective study, 42 eyes of 42 patients were initially treated with 3 consecutive monthly IVB injections (loading phase), after which they were selected for different additional therapies. For the TAE protocol, the baseline treatment interval was selected to be 8 weeks and was sequentially lengthened by 2 weeks if the central macular thickness (CMT) was <300 μm at 2 consecutive examinations.Among the 42 eyes, 8 eyes (19.0%) received the TAE treatment for 2 years. The BCVA was improved significantly from 0.37 ± 0.04 before treatment to 0.19 ± 0.04 logMAR units at 2 years after the TAE determined IVB injections (P < .05). The ratio of eyes with a gain of the BCVA by more than 2 lines was 37.5%. The CMT was significantly reduced from 515.4 ± 75.5 to 303.6 ± 45.0 μm after 2 years (P < .01). The mean number of TAE injection was 8.8 and the mean injection interval was 11.0 weeks.After the loading phase, 19.0% of patients can be treated with the TAE protocol. Although significant visual improvements were obtained after the TAE protocol, it does not apply to every DME case.
PMID
Related Publications

Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema.

Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema.

Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.

Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema.

Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 28422832
OWN - NLM
STAT- MEDLINE
DA  - 20170419
DCOM- 20170501
LR  - 20170501
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 16
DP  - 2017 Apr
TI  - Two year result of intravitreal bevacizumab for diabetic macular edema using
      treat and extend protocol.
PG  - e6406
LID - 10.1097/MD.0000000000006406 [doi]
AB  - To determine the efficacy of the treat and extend (TAE) protocol with
      intravitreal bevacizumab (IVB) for managing diabetic macular edema
      (DME).Retrospective, single-center study.For this retrospective study, 42 eyes of
      42 patients were initially treated with 3 consecutive monthly IVB injections
      (loading phase), after which they were selected for different additional
      therapies. For the TAE protocol, the baseline treatment interval was selected to 
      be 8 weeks and was sequentially lengthened by 2 weeks if the central macular
      thickness (CMT) was &lt;300 mum at 2 consecutive examinations.Among the 42 eyes, 8
      eyes (19.0%) received the TAE treatment for 2 years. The BCVA was improved
      significantly from 0.37 +/- 0.04 before treatment to 0.19 +/- 0.04 logMAR units
      at 2 years after the TAE determined IVB injections (P &lt; .05). The ratio of eyes
      with a gain of the BCVA by more than 2 lines was 37.5%. The CMT was significantly
      reduced from 515.4 +/- 75.5 to 303.6 +/- 45.0 mum after 2 years (P &lt; .01). The
      mean number of TAE injection was 8.8 and the mean injection interval was 11.0
      weeks.After the loading phase, 19.0% of patients can be treated with the TAE
      protocol. Although significant visual improvements were obtained after the TAE
      protocol, it does not apply to every DME case.
FAU - Sugimoto, Masahiko
AU  - Sugimoto M
AD  - Department of Ophthalmology, Mie University Graduate School of Medicine, Tsu,
      Mie, Japan.
FAU - Ichio, Atsushi
AU  - Ichio A
FAU - Nunome, Takayasu
AU  - Nunome T
FAU - Kondo, Mineo
AU  - Kondo M
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Angiogenesis Inhibitors)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - AIM
SB  - IM
MH  - Angiogenesis Inhibitors/*administration &amp; dosage
MH  - Bevacizumab/*administration &amp; dosage
MH  - Diabetic Retinopathy/diagnostic imaging/*drug therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Intravitreal Injections
MH  - Macular Edema/diagnostic imaging/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Organ Size
MH  - Prospective Studies
MH  - Retrospective Studies
MH  - Tomography, Optical Coherence
MH  - Treatment Outcome
PMC - PMC5406048
EDAT- 2017/04/20 06:00
MHDA- 2017/05/02 06:00
CRDT- 2017/04/20 06:00
AID - 10.1097/MD.0000000000006406 [doi]
AID - 00005792-201704210-00013 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Apr;96(16):e6406. doi: 10.1097/MD.0000000000006406.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>